Open AccessBMSCs ameliorate septic coagulopathy through suppressing inflammation in cecal ligation and puncture induced sepsis
Author(s) -
Shunyao Xu,
Zhen Zhou,
Hao Li,
Ziying Liu,
Xiaojun Pan,
Fen Wang,
Yueyue Huang,
Yong Li,
Yu Xiao,
Jingye Pan,
Cong Wang,
Dequan Li
Publication year - 2017
Publication title -
journal of cell science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.384
H-Index - 278
eISSN - 1477-9137
pISSN - 0021-9533
DOI - 10.1242/jcs.211151
Subject(s) - biology , sepsis , inflammation , coagulopathy , ligation , immunology , medicine , microbiology and biotechnology
Sepsis is an aggressive and life-threatening systemic inflammatory response with a high mortality. Inflammation and coagulation play crucial roles in the pathogenesis of sepsis in a mutually promoting manner. Unlike other single-target molecular therapies that have no obvious effects on clinical sepsis, the bone marrow stromal cell (BMSC) therapy offers a broader spectrum of activities ranging from immune and inflammation suppression to tissue regeneration. In this report, we demonstrated that BMSC injection attenuated the septic coagulopathy. It decreased the mortality, mitigated lung injury, and reduced the surge of proinflammatory factors in mice with sepsis induced by cecal ligation and puncture (CLP). In vitro cell model also revealed that co-culture with BMSCs reduced secretion of proinflammatory factors and injury of endothelial cells in response to lipopolysaccharides (LPS), an endotoxin of gram-negative bacteria. Together, our results demonstrated that BMSCs suppressed sepsis-induced inflammation, endothelial dysfunction, and defective coagulation.